Phase I Study of CC-486 Alone and in Combination With Carboplatin or Nab‑paclitaxel in Patients With Relapsed or Refractory Solid Tumors

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-17-3716
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Phase I, Pharmacokinetic, and Biological Study of Erlotinib in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2006English

Phase I Study of 17-Allylamino-17 Demethoxygeldanamycin, Gemcitabine and/or Cisplatin in Patients With Refractory Solid Tumors

Investigational New Drugs
OncologyPharmacology
2010English

Phase Ib Study of Cc-122 in Combination With Obinutuzumab (Ga101): Relapsed or Refractory (R/R) Patients With B-Cell Non-Hodgkin Lymphomas (Nhl)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

A Phase I Dose-Escalation Study of Selumetinib in Combination With Docetaxel or Dacarbazine in Patients With Advanced Solid Tumors

BMC Cancer
Cancer ResearchOncologyGenetics
2017English

A Multi-Center Phase I Study of Clofarabine, Etoposide and Cyclophosphamide in Combination in Pediatric Patients With Refractory or Relapsed Acute Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2009English

Erratum To: A Phase I Dose-Escalation Study of Selumetinib in Combination With Erlotinib or Temsirolimus in Patients With Advanced Solid Tumors

Investigational New Drugs
OncologyPharmacology
2017English

P1.16-21 Phase I / II Study of Carboplatin, Nab-Paclitaxel, and Concurrent Radiotherapy for Patients With Locally Advanced NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

A Phase I Trial of Dasatinib, an SRC-Family Kinase Inhibitor, in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Recurrent Ovarian Cancer

Clinical Cancer Research
Cancer ResearchOncology
2012English

Combination of Nivolumab and Bendamustine in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy